Biomarkers are like pieces of a puzzle that can give doctors a more well-defined picture of a patient's non-small cell lung cancer.
Thanks to advancements in lung cancer research, doctors have found that every lung cancer is different and that they can use biomarkers to uncover some of the characteristics of a patient's lung cancer. Biomarker testing is now widely recommended in NSCLC and by testing for biomarkers including EGFR, ALK, ROS-1 and PD-L1, doctors have information to help make treatment decisions.
In simple terms, biomarkers are like pieces to a puzzle that can give doctors a more well-defined picture of a patient's NSCLC. With the results of a biomarker test, doctors can plan the best treatment path forward for a patient.
Leading lung cancer patient advocacy groups supporting the program include Bonnie J. Addario Lung Cancer Foundation, Free to Breathe, Lung Cancer Alliance, Lung Cancer Foundation of America, Lung Cancer Research Foundation, and LUNGevity. These organizations have made it their mission to support people impacted by lung cancer through education, resources and research.
Bellamy Young knows firsthand what people with lung cancer and their loved ones are going through. Young’s father went through ten months of treatment for lung cancer before he passed away from the disease.
“When my Pop was diagnosed with lung cancer, we felt helpless and confused. I just wanted to know as much as I could to help us understand and manage his treatment and care,” she explains.
Young feels strongly that being informed is one of the keys to feeling more in control of your lung cancer journey. Young is joining the Test. Talk. Take Action. campaign to encourage those impacted by NSCLC to get the facts about biomarkers and talk with their health care providers about testing.